Recombinant Somatropin
PreclinicalSmall molecule
Merck & Co.Recombinant Somatropin is one of 46 small molecule programs targeting Small for gestational age. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
45
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
79 competitors in Growth
#DrugCompanyPhaseTrials
1Growth Hormone
PfizerPhase 3
Neo-Synephrine
EExela Pharma Sciences, LLC.
Phase 3
Recombinant Human Growth Hormone
Changchun GeneScience Pharmaceutical Co., Ltd.Phase 3
Piqray
NovartisPhase 2
Acipimox
Boehringer IngelheimPhase 2
Lenvima
EisaiPreclinical
Zolymbus
AbbViePreclinical
Zyloprim
Jazz PharmaceuticalsPreclinical
Aricept
EisaiPreclinical
TY-9591
TTYK Medicines, Inc
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Recombinant Somatropin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company